Kumatakenin

Kumatakenin

SCHEMBL3351483

COc1cc(O)c2c(=O)c(OC)c(-c3ccc(O)cc3)oc2c1

nearest known ligand 0.90

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.83
CYP3A4 P08684 3/20 0.83
RECQL P46063 3/20 0.83
CYP2D6 P10635 2/20 0.83
POLB P06746 2/20 0.83
APEX1 P27695 2/20 0.83
POLH Q9Y253 2/20 0.83
MCL1 Q07820 1/20 0.83
PLG P00747 1/20 0.81
NOX4 Q9NPH5 1/20 0.81
MAOA P21397 1/20 0.79
ABCG2 Q9UNQ0 5/20 0.78
ABCB1 P08183 4/20 0.78
ABCC1 P33527 2/20 0.78
MAPT P10636 4/20 0.67
TUBB4A P04350 2/20 0.67
TUBB P07437 2/20 0.67
TUBA3C P0DPH7 2/20 0.67
TUBA1B P68363 2/20 0.67
TUBA4A P68366 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Kumatakenin SCHEMBL29681818 1.00 KDM4E (0.83) KDM4ECYP3A4RECQLCYP2D6POLB
SCHEMBL30131217 0.95 CYP3A4 (0.88) KDM4ECYP3A4RECQLCYP2D6POLB
SCHEMBL4649968 0.95 CYP3A4 (0.88) KDM4ECYP3A4RECQLCYP2D6POLB
SCHEMBL11096763 0.91 ABCG2 (0.77) KDM4ECYP3A4RECQLCYP2D6POLB
SCHEMBL18130384 0.91 ABCB1 (0.83) KDM4ECYP3A4RECQLCYP2D6POLB
Isokaempferide SCHEMBL29721227 0.91 POLH (1.00) KDM4ECYP3A4RECQLCYP2D6POLB
Isokaempferide SCHEMBL1628023 0.91 POLH (1.00) KDM4ECYP3A4RECQLCYP2D6POLB
SCHEMBL29825010 0.90 PLG (1.00) KDM4ECYP3A4RECQLCYP2D6POLB
SCHEMBL828941 0.90 PLG (1.00) KDM4ECYP3A4RECQLCYP2D6POLB
SCHEMBL15635199 0.90 ADORA3 (0.83) KDM4ECYP3A4RECQLCYP2D6POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200164047-A1 THERAPY AND DIAGNOSIS OF DISEASE CHARACTERIZED BY ALTERATIONS IN THE DNA DAMAGE RESPONSE UNIVERSITÀ DEGLI STUDI DI MILANO (IT) 2020-05-28 US claimed
EP-3642337-A1 THERAPY AND DIAGNOSIS OF DISEASE CHARACTERIZED BY ALTERATIONS IN THE DNA DAMAGE RESPONSE IFOM - Fondazione Istituto FIRC di Oncologia Molecolare (IT) 2020-04-29 EP claimed
WO-2018211137-A1 THERAPY AND DIAGNOSIS OF DISEASE CHARACTERIZED BY ALTERATIONS IN THE DNA DAMAGE RESPONSE UNIVERSITÀ DEGLI STUDI DI MILANO (IT) 2018-11-22 WO claimed
EP-0290442-A4 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS. CHEMEX PHARMACEUTICALS INC (US) 1990-07-03 EP claimed
EP-0290442-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS CHEMEX PHARMACEUTICALS, INC. (US) 1988-11-17 EP claimed
US-4774229-A ANTITUMOR AGENTS, SKIN DISORDERS, CANCER TREATMENT CHEMEX PHARMACEUTICALS, INC. (US) 1988-09-27 US claimed
WO-1988003805-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS CHEMEX PHARMACEUTICALS, INC. (US) 1988-06-02 WO claimed
WO-1987006833-A1 MODIFICATION OF PLANT EXTRACTS FROM ZYGOPHYLLACEAE CHEMEX PHARMACEUTICALS, INC. (US) 1987-11-19 WO claimed
US-4352792-A 3-Alkoxyflavone antiviral agents HOFFMANN-LA ROCHE INC. (US) 1982-10-05 US claimed
EP-0019081-A1 Flavone derivatives, their preparation, these novel and known flavones as antiviral agents, and pharmaceutical compositions containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1980-11-26 EP claimed
US-20200164047-A1 THERAPY AND DIAGNOSIS OF DISEASE CHARACTERIZED BY ALTERATIONS IN THE DNA DAMAGE RESPONSE UNIVERSITÀ DEGLI STUDI DI MILANO (IT) 2020-05-28 US disclosed
EP-3642337-A1 THERAPY AND DIAGNOSIS OF DISEASE CHARACTERIZED BY ALTERATIONS IN THE DNA DAMAGE RESPONSE IFOM - Fondazione Istituto FIRC di Oncologia Molecolare (IT) 2020-04-29 EP disclosed
WO-2018211137-A1 THERAPY AND DIAGNOSIS OF DISEASE CHARACTERIZED BY ALTERATIONS IN THE DNA DAMAGE RESPONSE UNIVERSITÀ DEGLI STUDI DI MILANO (IT) 2018-11-22 WO disclosed
US-20140234271-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS THE HOSPITAL FOR SICK CHILDREN (CA) 2014-08-21 US disclosed
US-8748177-B2 Compositions for proliferation of cells and related methods THE HOSPITAL FOR SICK CHILDREN (CA) 2014-06-10 US disclosed
US-4774229-A ANTITUMOR AGENTS, SKIN DISORDERS, CANCER TREATMENT CHEMEX PHARMACEUTICALS, INC. (US) 1988-09-27 US disclosed
WO-1987006833-A1 MODIFICATION OF PLANT EXTRACTS FROM ZYGOPHYLLACEAE CHEMEX PHARMACEUTICALS, INC. (US) 1987-11-19 WO disclosed
EP-0019081-B1 FLAVONE DERIVATIVES, THEIR PREPARATION, THESE NOVEL AND KNOWN FLAVONES AS ANTIVIRAL AGENTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1984-10-24 EP disclosed
US-4352792-A 3-Alkoxyflavone antiviral agents HOFFMANN-LA ROCHE INC. (US) 1982-10-05 US disclosed
EP-0019081-A1 Flavone derivatives, their preparation, these novel and known flavones as antiviral agents, and pharmaceutical compositions containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1980-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200164047-A1 THERAPY AND DIAGNOSIS OF DISEASE CHARACTERIZED BY ALTERATIONS IN THE DNA DAMAGE RESPONSE PPP3CA, PPP5C, PPP3R1 KDM4E 3052/4885CYP3A4 4698/4885RECQL 139/4885
US-20140234271-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS MKI67, KRT18, PROX1 KDM4E 674/4885CYP3A4 4005/4885RECQL 1434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.